Pompe Disease: Clinical Trials

10 trials for Pompe Disease, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 terminated, 2 unknown, 1 active not recruiting. 10 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 410Completed 5, Terminated 2, Unknown 2, Active not recruiting 1

Follow Pompe Disease: new trials by email Literature Review of Pompe Disease trials Research Report on Pompe Disease

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of Avalglucosidase Alfa in Patients With Non-classic Pompe Disease Aged ≥ 5 Years
Avalglucosidase Alfa - Glycogen Storage Disease Type II Late Onset, Pompe Disease (Late-onset)
Phase 4Active not recruitingIris Plug62022-10-132026-06-17
Immune Modulation Therapy for Pompe Disease
Rituximab, intravenous immune globulin, Bortezomib - Pompe Disease
Phase 4UnknownNational Taiwan University Hospital82015-08-012016-04-15
Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease
alglucosidase alfa - Pompe Disease, Glycogen Storage Disease Type II (GSD II)
Phase 4CompletedGenzyme, a Sanofi Company212014-11-032022-03-28
CPAP for Infantile Pompe Disease
continuous positive airway pressure - Pompe Disease
Phase 4UnknownNational Taiwan University Hospital32014-06-012015-04-01
Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease
Salbutamol - Pompe Disease
Phase 4CompletedNational Taiwan University Hospital142013-10-012016-09-20
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
Alglucosidase alfa - Pompe Disease
Phase 4TerminatedGenzyme, a Sanofi Company1132012-03-012015-12-08
An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease
Alglucosidase Alfa, Methotrexate, Rituximab - Pompe Disease, Glycogen Storage Disease Type II
Phase 4CompletedGenzyme, a Sanofi Company42009-10-012014-05-13
Immune Tolerance Induction Study
Myozyme® (alglucosidase alfa) - Pompe Disease, Glycogen Storage Disease Type II (GSD-II)
Phase 4TerminatedGenzyme, a Sanofi Company42008-12-142022-04-07
Growth and Development Study of Alglucosidase Alfa
alglucosidase alfa - Pompe Disease, Glycogen Storage Disease Type II (GSD-II)
Phase 4CompletedGenzyme, a Sanofi Company122008-08-262022-08-26
High Dose or High Dose Frequency Study of Alglucosidase Alfa
alglucosidase alfa - Pompe Disease, Glycogen Storage Disease Type II (GSD-II)
Phase 4CompletedGenzyme, a Sanofi Company132007-05-012014-03-07

Narrower conditions

Glycogen Storage Disease Type II (10)  ·  Heartburn (1)

Broader conditions

Brain Diseases (10)  ·  Brain Diseases, Metabolic (10)  ·  Brain Diseases, Metabolic, Inborn (10)  ·  Carbohydrate Metabolism, Inborn Errors (10)  ·  Central Nervous System Diseases (10)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10)  ·  Genetic Diseases, Inborn (10)  ·  Glycogen Storage Disease (10)  ·  Lysosomal Storage Diseases (10)  ·  Lysosomal Storage Diseases, Nervous System (10)  ·  Metabolic Diseases (10)  ·  Metabolism, Inborn Errors (10)  ·  Nervous System Diseases (10)  ·  Nutritional and Metabolic Diseases (10)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

GAA protein, human (6)  ·  Methotrexate (2)  ·  Rituximab (2)  ·  Albuterol (1)  ·  Bortezomib (1)  ·  Continuous Positive Airway Pressure (1)  ·  Immunoglobulins, Intravenous (1)

Sponsors

Genzyme, a Sanofi Company (6)  ·  National Taiwan University Hospital (3)  ·  Iris Plug (1)

Countries

United States (6)  ·  Taiwan (3)  ·  Australia (1)  ·  Bulgaria (1)  ·  Canada (1)  ·  India (1)  ·  Israel (1)  ·  Netherlands (1)  ·  Russia (1)  ·  Ukraine (1)  ·  United Kingdom (1)

Top investigators

Yin-Hsiu Chien, MD, PhD (2)  ·  Nadine van der Beek, MD PHD (1)  ·  Yin-Hsiu Chien (1)

Results publications

PMID 29565424, PMID 31086307, PMID 34420548, PMID 36214004, PMID 37705424, PMID 38715621

NIH funding

2015 (1), 2019 (1)